A Therapy For European Patent Term Extensions
In its ruling, the CJEU significantly liberalized the current practice for granting supplementary protection certificates ("SPCs"), reducing the limitations imposed on the grant or duration of SPCs by earlier marketing authorizations ("MAs") for the same active pharmaceutical ingredient ("API").
The requirements for the grant of an SPC and for the computation of its duration are laid down...
Already a subscriber? Click here to login